|
Jul 14
|
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial
|
|
Jul 11
|
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
|
|
Jun 30
|
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
|
|
Jun 24
|
Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375
|
|
Jun 24
|
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
|
|
Jun 20
|
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
|
|
May 28
|
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
|
|
May 28
|
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
|
|
May 27
|
US High Growth Tech Stocks to Watch in May 2025
|
|
May 23
|
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC
|
|
May 22
|
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
|
|
May 20
|
Tempus partners with Verastem for companion diagnostic development
|
|
Feb 20
|
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
|
|
Jan 2
|
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
|
|
Dec 31
|
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application
|
|
Dec 31
|
Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell
|
|
Dec 30
|
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
|
|
Jul 29
|
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
|
|
Jul 24
|
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
|
|
Jul 23
|
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
|